Belvarafenib

Belvarafenib (developed by Hanmi Pharmaceuticals and Genentech) is a small molecule RAF dimer (type II) inhibitor which shows anti-tumor clinical activity in cancer patients with BRAFV600E- and NRAS- mutations.